- Question from Maher: Do you think the CYP2D6 test will ever become protocol before women are prescribed tamoxifen?
- Answers - Eric Winer, M.D. There were two studies at San Antonio, both of which very strongly indicated that the CYP2D6 test was not of value. While there are additional studies that will be reported, in my mind, these two large studies that were just reported should put an end to testing for CYP2D6 unless truly compelling data become available. I fear that testing has the potential to lead to far more harm than good. In particular in premenopausal women where tamoxifen is the standard, there are women who have come off tamoxifen because of testing and I worry that substituting other agents for tamoxifen in premenopausal women could result in real harm.
On Wednesday, December 15, 2010, our Ask-the-Expert Online Conference was called Updates from the 2010 San Antonio Breast Cancer Symposium. Eric Winer, M.D. and Marisa Weiss, M.D. answered your questions about the latest updates on breast cancer risk, screening, and treatment in early and metastatic breast cancer.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.